MiR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice

Cell Death and Disease

Volumn 8, Issue 4, 2017, Pages

  Rodrigues, Pedro M ^a   Afonso, Marta B ^a   Simaõ, André L ^a   Carvalho, Catarina C ^b   Trindade, Alexandre ^b,c   Duarte, António ^b,c   Borralho, Pedro M ^a   MacHado, Mariana V ^d   Cortez Pinto, Helena ^d   Rodrigues, Cecília Mp ^a   Castro, Rui E ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^d HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; MICRORNA 21; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; MICRORNA; MIRN21 MICRORNA, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL VACUOLE; CHOLESTEROL METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FAST FOOD; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER CELL; LIVER FIBROSIS; LIVER PARENCHYMA; MALE; METABOLIC SYNDROME X; MOUSE; MUSCLE BIOPSY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUNEL ASSAY; ADVERSE EFFECTS; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; APOPTOSIS; CHENODEOXYCHOLIC ACID; DISEASE MODELS, ANIMAL; FAST FOODS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MICE; MICE, KNOCKOUT; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR ALPHA; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 85017474560     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.172     Document Type: Article

References (48)

1. Larter CZ, Yeh MM. Animal models of NASH: Getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23: 1635-1648.
2. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009; 25: 230-237.
3. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233.
4. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013; 18: 282-289.
5. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008; 48: 1810-1820.
6. Loyer X, Paradis V, Henique C, Vion AC, Colnot N, Guerin CL et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut 2016; 65: 1882-1894.
7. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50: 1152-1161.
8. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 2016; 65: 1850-1860.
9. Calo N, Ramadori P, Sobolewski C, Romero Y, Maeder C, Fournier M et al. Stress-activated miR-21/miR-21∗in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut 2016; 65: 1871-1881.
10. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009; 49: 1176-1184.
11. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: Potential therapeutic targets. Biochim Biophys Acta 2012; 1821: 809-818.
12. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006; 31: 572-580.
13. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-997.
14. Fuchs M. Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012: 934396.
15. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology 2011; 53: 1023-1034.
16. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009; 328: 116-122.
17. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965.
18. Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H et al. Necroptosis is a key pathogenic event in human and experimental murine models of nonalcoholic steatohepatitis. Clin Sci (Lond) 2015; 129: 721-739.
19. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014; 6: 1062-1074.
20. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: Mechanisms and clinical relevance. Gastroenterology 2014; 147: 765-783 e764.
21. Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013; 58: 119-125.
22. Machado MV, Michelotti GA, Pereira Tde A, Boursier J, Kruger L, Swiderska-Syn M et al. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut 2015; 64: 1148-1157.
23. Ferreira DM, Castro RE, Machado MV, Evangelista T, Silvestre A, Costa A et al. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia 2011; 54: 1788-1798.
24. Itagaki H, Shimizu K, Morikawa S, Ogawa K, Ezaki T. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Pathol 2013; 6: 2683-2696.
25. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A et al. Fast food diet mouse: Novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011; 301: G825-G834.
26. Spahis S, Delvin E, Borys JM, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal 2017; 26: 519-541.
27. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
28. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435.
29. Afonso MB, Rodrigues PM, Simao AL, Castro RE. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med 2016; 5: E30.
30. Szabo G, Csak T. Role of microRNAs in NAFLD/NASH. Dig Dis Sci 2016; 61: 1314-1324.
31. Ferreira DM, Simao AL, Rodrigues CM, Castro RE. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J 2014; 281: 2503-2524.
32. Zheng L, Lv GC, Sheng J, Yang YD. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol 2010; 25: 156-163.
33. Ding J, Li M, Wan X, Jin X, Chen S, Yu C et al. Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci Rep 2015; 5: 13729.
34. Johnson ES, Lindblom KR, Robeson A, Stevens RD, Ilkayeva OR, Newgard CB et al. Metabolomic profiling reveals a role for caspase-2 in lipoapoptosis. J Biol Chem 2013; 288: 14463-14475.
35. Rodrigues PM, Afonso MB, Simao AL, Borralho PM, Rodrigues CM, Castro RE. Corrigendum: Inhibition of NF-kappaB by deoxycholic acid induces miR-21/PDCD4-dependent hepatocellular apoptosis. Sci Rep 2016; 6: 27828.
36. Ma X, Conklin DJ, Li F, Dai Z, Hua X, Li Y et al. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun 2015; 6: 7151.
37. Ii H, Yokoyama N, Yoshida S, Tsutsumi K, Hatakeyama S, Sato T et al. Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice. PloS ONE 2009; 4: E8089.
38. Kanai S, Ishihara K, Kawashita E, Tomoo T, Nagahira K, Hayashi Y et al. ASB14780, an orally active inhibitor of group IVA phospholipase A2, is a pharmacotherapeutic candidate for nonalcoholic fatty liver disease. J Pharmacol Exp Ther 2016; 356: 604-614.
39. Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metabol 2016; 27: 84-95.
40. Martinez-Clemente M, Claria J, Titos E. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. Curr Opin Clin Nutr Metab Care 2011; 14: 347-353.
41. Hwang JH, Stein DT, Barzilai N, Cui MH, Tonelli J, Kishore P et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: In vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 2007; 293: E1663-E1669.
42. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005; 48: 634-642.
43. Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 2015; 125: 141-156.
44. Han CY, Kim TH, Koo JH, Kim SG. Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function. Arch Pharmacal Res 2016; 39: 1062-1074.
45. Ratziu V. Novel pharmacotherapy options for NASH. Dig Dis Sci 2016; 61: 1398-1405.
46. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582 e571.
47. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013; 58: 1941-1952.
48. Sanchez-Nino MD, Ortiz A. HCV infection and miravirsen. N Engl J Med 2013; 369: 877-878.